The huge progress made in the past few years to treat CRPC with hormonal manipulation or AR blockade caused confidence in prostate cancer therapy but may be compromised by resistance mechanisms acquired under these novel treatments (Yuan et al. 2013). The gene discussed is AR; the disease is prostate cancer.